Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Peramivir is the first intravenously administered neuramidase inhibitor for immediate delivery of an effective single-dose treatment in patients with influenza. However, limited data are available on intravenous (IV) peramivir treatment compared to oral oseltamivir for these patients. Materials and Methods: With a systematic review and meta-analysis, we compared the efficacy of IV peramivir with oral oseltamivirfor treatment of patients with seasonal influenza. MEDLINE, EMBASE, and Cochrane Central Register were searched for relevantclinical trials. Results: A total of seven trials [two randomized controlled trials (RCTs) and five non-randomized observational trials] involving 1676 patients were finally analyzed. The total number of peramivir- and oseltamivir-treated patients was 956 and 720, respectively. Overall, the time to alleviation of fever was lower in the peramivir-treated group compared with the oseltamivir-treated group [mean difference (MD), -7.17 hours; 95% confidence interval (CI) -11.00 to -3.34]. Especially, pooled analysis of observational studies(n=4) and studies of outpatients (n=4) demonstrated the superiority of the peramivir-treated group (MD, -7.83 hours; 95% CI -11.81 to -3.84 and MD, -7.71 hours; 95% CI -11.61 to -3.80, respectively). Mortality, length of hospital stay, change in virus titer 48 hours after admission, and the incidence of adverse events in these patients were not significantly different between the two groups. Conclusion: IV peramivir therapy might reduce the time to alleviation of fever in comparison with oral oseltamivir therapy in patientswith influenza; however, we could not draw clear conclusions from a meta-analysis because of the few RCTs available and methodological limitations.
Abstract
Purpose: Peramivir is the first intravenously administered neuramidase inhibitor for immediate delivery of an effective single-dose treatment in patients with influenza. However, limited data are available on intravenous (IV) peramivir treatment compared to oral oseltamivir for these patients. Materials and Methods: With a systematic review and meta-analysis, we compared the efficacy of IV peramivir with oral oseltamivirfor treatment of patients with seasonal influenza. MEDLINE, EMBASE, and Cochrane Central Register were searched for relevantclinical trials. Results: A total of seven trials [two randomized controlled trials (RCTs) and five non-randomized observational trials] involving 1676 patients were finally analyzed. The total number of peramivir- and oseltamivir-treated patients was 956 and 720, respectively. Overall, the time to alleviation of fever was lower in the peramivir-treated group compared with the oseltamivir-treated group [mean difference (MD), -7.17 hours; 95% confidence interval (CI) -11.00 to -3.34]. Especially, pooled analysis of observational studies(n=4) and studies of outpatients (n=4) demonstrated the superiority of the peramivir-treated group (MD, -7.83 hours; 95% CI -11.81 to -3.84 and MD, -7.71 hours; 95% CI -11.61 to -3.80, respectively). Mortality, length of hospital stay, change in virus titer 48 hours after admission, and the incidence of adverse events in these patients were not significantly different between the two groups. Conclusion: IV peramivir therapy might reduce the time to alleviation of fever in comparison with oral oseltamivir therapy in patientswith influenza; however, we could not draw clear conclusions from a meta-analysis because of the few RCTs available and methodological limitations.
참고문헌 (19)
- "Vaccines against influenza WHO position paper–November 2012", Wkly Epidemiol Rec, 87, pp.461~476 (2012)
- "Vaccine Recommendations of the ACIP"[URL]
- Wester A, "Peramivir injection in the treatment of acute influenza:a review of the literature", Infect Drug Resist, 9, pp.201~214 (2016)
- Birnkrant D, "The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza", N Engl J Med, 361, pp.2204~2207 (2009)
- Kohno S, "Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection", Antimicrob Agents Chemother, 54, pp.4568~4574 (2010)
- Kohno S, "Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients", Antimicrob Agents Chemother, 55, pp.2803~2812 (2011)
- Ison MG, "A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults", Antivir Ther, 18, pp.651~661 (2013)
- Kohno S, "Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection", Antimicrob Agents Chemother, 55, pp.5267~5276 (2011)
- Hikita T, "Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients", Int J Pediatr, 2012, pp.834181~ (2012)
- Shobugawa Y, "Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan", J Infect Chemother, 18, pp.858~864 (2012)
- Takemoto Y, "Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013", Chemotherapy, 59, pp.373~378 (2013)
- Yoo JW, "Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza", J Med Virol, 87, pp.1649~1655 (2015)
- Yoshino Y, "Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan", Clin Respir J, 9, pp.228~232 (2015)
- "The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses"[URL]
- Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Alame MM, "Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections", Front Microbiol, 7, pp.450~ (2016)
- de Jong MD, "Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients", Clin Infect Dis, 59, pp.e172~e185 (2014)
- Barroso L, "Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment", Antivir Ther, 10, pp.901~910 (2005)
- Hata A, "Safety and efficacy of peramivir for influenza treatment", Drug Des Devel Ther, 8, pp.2017~2038 (2014)